Flinn secures 20 million US dollars for AI-supported automation in MedTech and Pharma

The pan-European company Flinn has received 20 million US dollars in a new financing round. The round is led by HV Capital, supported by US healthcare specialist BHI - Bertelsmann Healthcare Investments and existing investors Cherry Ventures, Speedinvest and SquareOne. The fresh capital is intended to expand the platform across the entire product lifecycle of medtech and pharma products and accelerate expansion in Europe and the USA.

AI-supported automation for regulation and quality

Flinn develops software that automates regulatory and quality-related processes. The AI replaces manual, document-heavy work with intelligent, scalable workflows. This enables manufacturers to shorten development cycles, ensure compliance and focus resources on innovative tasks.

Regulatory and quality processes are one of the biggest cost drivers in the medtech sector today. With the financing, we can extend our infrastructure to further life cycle phases and support manufacturers worldwide.

Bastian Krapinger-Rüther, Co-Founder and Co-CEO of Flinn

Companies such as Carl Zeiss, Philips and Paul Hartmann already use Flinn to efficiently manage regulatory complexity and maintain the highest quality standards worldwide.

Strategic expansion along the product life cycle

Flinn has a clear product vision, excellent customer feedback and a team that acts quickly and with focus. We look forward to accompanying the company on its next chapter of growth.

Felix Klühr, General Partner at HV Capital

With the new financing, Flinn plans to extend automation to the early development phases and commercial processes. The goal is to create an end-to-end, automated compliance and quality backbone for the entire lifecycle of medical products. The international expansion will be supported by the expertise and networks of HV Capital and Bertelsmann Healthcare Investments, particularly for scaling in the USA.

Tim Schneider, Partner at BHI:"Flinn addresses a clear gap in the US market and offers MedTech teams a unique, user-centric system. We are excited to support their expansion into the US."